Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now early-phase tilt small index

Fallopian Tube: early-phase trial registry

1 of 4 indexed Fallopian Tube trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #4,115 of 28,707 conditions by registered trial count.

4 US clinical trials · 1 currently recruiting · #4,115 of 28,707 conditions by registered trial count

Fallopian Tube: 4 US clinical trials tracked, 1 recruiting.

Fallopian Tube is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition fallopian-tube

OPEN 1 | RECR 25% | LATE 0 | EARLY 3 | RANK #4115 | SPON 2

Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Fallopian Tube (this)25%
Open-enrollment share among volume-matched conditions near Fallopian Tube

Fallopian Tube lists 1 open slots (25% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Fallopian Tube on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Fallopian Tube is recruiting below its size-band peers.

    1 of 4 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 12Phase 21

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 1

Named interventions

Most-linked intervention names on Fallopian Tube records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cytoreductive surgery Procedure
2 trials
18F-Fluoro-2-deoxy-D-lucose Radiation
1 trials
Carboplatin and Paclitaxel Drug
1 trials
Paclitaxel/Bev + ZA (experimental) Drug
1 trials
Paclitaxel/Bev (control) Drug
1 trials
mirvetuximab soravtansine (MIRV; IMGN853) Drug
1 trials
Ipilimumab Drug
1 trials
Nivolumab Drug
1 trials

US sites by state

Facility locations filed on Fallopian Tube trials. A trial with sites in several states counts in each.

New York 2 trials
Virginia 1 trials
Texas 1 trials
Pennsylvania 1 trials
Oklahoma 1 trials
Ohio 1 trials
Mississippi 1 trials
Minnesota 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Fallopian Tube page

4 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fallopian Tube condition card totals 4 registered trials; most-linked intervention Cytoreductive surgery; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.